Clene (CLNN) Non-Current Assets (2019 - 2026)
Clene (CLNN) posted Non-Current Assets of $8.1 million for Q2 2026, down 11.22% on a QoQ basis from $9.2 million in Q4 2025, and down 19.85% year-over-year from $10.1 million in Q2 2025.
Analysis
Clene (CLNN) Non-Current Assets (2019 - 2026) Analysis & Trends
Clene has reported Non-Current Assets for 8 years, with the latest figure at $8.1 million in Q2 2026.
- On a quarterly basis, Non-Current Assets fell 19.85% year-over-year to $8.1 million in Q2 2026; TTM through Jun 2026 was $37.1 million, a 15.46% decrease from a year earlier, with the FY2025 full-year figure at $9.2 million, down 18.12% from the prior year.
- Non-Current Assets was $8.1 million for Q2 2026 at Clene, down from $9.2 million in the prior quarter.
- The five-year high for Non-Current Assets was $15.3 million in Q4 2022, with the low at $8.1 million in Q2 2026.
- Average Non-Current Assets over 5 years is $12.2 million, with a median of $12.4 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets surged 152.73% in 2022, then retreated 19.85% in 2026.
- Over 5 years, Non-Current Assets stood at $15.3 million in 2022, then retreated by 11.83% to $13.5 million in 2023, then fell by 17.12% to $11.2 million in 2024, then retreated by 18.12% to $9.2 million in 2025, then fell by 11.22% to $8.1 million in 2026.
- The last three Non-Current Assets figures came in at $8.1 million (Q2 2026), $9.2 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 159.77 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 113.37 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | 294.93 Mn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 1.85 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 3.74 Bn |
| 10 | Clene | 45.69 Mn | 45.69 Mn | 54,000.00 | 8.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.13 Mn |
| Dec 31, 2025 | 9.15 Mn |
| Sep 30, 2025 | 9.64 Mn |
| Jun 30, 2025 | 10.14 Mn |
| Mar 31, 2025 | 10.64 Mn |
| Dec 31, 2024 | 11.18 Mn |
| Sep 30, 2024 | 11.87 Mn |
| Jun 30, 2024 | 12.42 Mn |
| Mar 31, 2024 | 12.96 Mn |
| Dec 31, 2023 | 13.49 Mn |
| Sep 30, 2023 | 13.99 Mn |
| Jun 30, 2023 | 14.47 Mn |
| Mar 31, 2023 | 15.07 Mn |
| Dec 31, 2022 | 15.30 Mn |
| Sep 30, 2022 | 14.52 Mn |
| Jun 30, 2022 | 12.96 Mn |
| Mar 31, 2022 | 10.91 Mn |
| Dec 31, 2021 | 8.48 Mn |
| Sep 30, 2021 | 7.64 Mn |
| Jun 30, 2021 | 5.13 Mn |